Ability Biotherapeutics Welcomes Angèle Maki, PhD to its Board of Directors
MONTREAL — Ability Biotherapeutics, a biotechnology leader focused on developing next-generation antibody therapies, is pleased to announce the appointment of Angèle Maki, PhD to its Board of Directors.
Article content
Article content
Dr. Maki brings over 20 years of experience in the biopharmaceutical industry, with a distinguished track record of leadership in business development and strategic partnerships across both emerging biotech ventures and global pharmaceutical companies. She currently serves as Chief Business Officer at Callio Therapeutics, a company realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes.
Article content
Over the course of her career, Dr. Maki has held senior roles at leading organizations including Medarex (acquired by Bristol Myers Squibb), Bristol Myers Squibb, Genentech, Merck & Co., Eli Lilly, ReCode Therapeutics, and Hummingbird Bioscience which spun out Callio Therapeutics. She has led and executed a broad spectrum of transactions across modalities and therapeutic areas—from early research collaborations to therapeutic licensing agreements and acquisitions—and played a key role in the venture strategy while at Eli Lilly.
Article content
'We are thrilled to welcome Angèle to our Board of Directors at this pivotal stage in Ability's growth,' said Giles Day, Chief Executive Officer of Ability Biotherapeutics. 'Her deep experience in business development, licensing, and strategic partnerships across both biotech and pharma will be invaluable as we advance our lead antibody programs toward preclinical development and prepare for our first human clinical trials. As Ability continues to build momentum, Angèle's insights and leadership will help guide us through the critical decisions that lie ahead.'
Article content
In addition to her corporate roles, Dr. Maki is a passionate advocate for innovation and entrepreneurship. She currently serves as Board Chair of Canadian Entrepreneurs in Life Sciences (CELS), a non-profit organization supporting emerging leaders in the sector. Dr. Maki earned her Ph.D. in Biological Chemistry from Stanford University and holds a B.Sc. in Chemistry from the University of Winnipeg.
Article content
'I'm truly delighted to join the Board of Directors at Ability Biotherapeutics,' said Dr. Maki. 'Ability's bold mission to revolutionize targeted antibody therapies for cancer and autoimmune diseases, combined with the team's scientific excellence and innovative spirit, makes it an incredibly exciting company to support. I look forward to contributing to its continued growth as it advances toward clinical development and strives to improve patient outcomes.'
Article content
About Ability Biotherapeutics
Ability Biotherapeutics is the next-generation biotherapeutics company developing logic-gated antibodies with exceptional contextual selectivity and stability, driving safer, more effective immunotherapies for cancer and autoimmune diseases. Its proprietary platform, AbiLeap™, uses generative AI powered by one of the largest and exclusively held, therapeutically relevant human antibody databases, providing distinct insights for sequence space exploration. Combining AI with in vitro display and screening technologies, AbiLeap™ generates fully human antibodies that are conditionally activated and multi-specific, directing therapeutic targeting to specific cells and disease sites. This approach enables solutions for indications with high unmet clinical needs by reducing toxicity and significantly broadening the therapeutic window, maximizing treatment benefits. Ability's experienced team is committed to revolutionizing targeted therapeutics to transform patient outcomes and redefine industry standards. To learn more, visit ability.bio, their LinkedIn page, or contact them at partnering@ability.bio.
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Calgary Herald
23 minutes ago
- Calgary Herald
Japanese trade deal with U.S. creates lower tariff rate for vehicles than Canada faces
Article content A new U.S.-Japan trade deal reportedly gives the Asian country a 15 per cent flat tariff rate — providing a potential edge in key export areas such as auto manufacturing, where Canadian finished vehicles currently face a 25 per cent tariff rate. Article content United States President Donald Trump announced the deal with Japan on Tuesday but details remain vague, as no official text of the deal was released. Article content Article content Article content That is similar to other trade deals that the U.S. has announced in recent weeks, where the details remain undisclosed. Still, as Canada inches toward an August deadline on negotiations with the U.S., auto industry professionals offered mixed reactions as to how Japan's deal could affect the competitiveness of Canada's sector. Article content Article content 'If you're Japan, and you're looking around and saying where are my competitors, you're feeling pretty good,' said Eric Miller, president of Washington, D.C.-based Rideau Potomac Strategy Group, a consulting firm on trade policy. 'Autos are about a quarter of their exports, and the auto access was a significant piece of this.' Article content Indeed, according to the World Bank, auto and related exports accounted for about 20 per cent of Japan's trade in 2022. Article content Within Canada's auto sector, the agreement spurred mixed reactions. Article content Article content On the one hand, if Japanese-built vehicle exports to the U.S. face a lower duty than Canadian built ones, this could in theory incentivize some automakers to move production to Japan. Article content Article content On the other hand, that is considered unlikely by many within the auto industry who hold out hope that in the end, Canadian-built autos are likely to receive a lower tariff rate than Japan. Article content 'That's certainly the hope,' said David Adams, president of the Global Automakers of Canada, a lobbying group that represents Honda Motor Co. Ltd. and Toyota Motor Corp. among other foreign automakers. Article content He and others say that vehicles built in Canada, often in border towns such as Windsor, have far more spillover effects in terms of creating jobs in the U.S. than vehicles built in other countries that are separated from the U.S. by an ocean. Article content In reality, Canadian automakers are already paying below 15 per cent in many cases. That is because the Trump Administration adjusted its policies such that automakers can declare the value of any Canada-United States-Mexico Agreement (CUSMA) compliant parts contained within a vehicle and deduct that amount from the total value of the vehicle subject to a tariff.
Globe and Mail
23 minutes ago
- Globe and Mail
Tesla Inc: Guggenheim Maintains 'Sell', $175 Target Ahead of Earnings
Tesla Inc. (TSLA) (About (STA Research): Is a Canadian investment research company specializing in advanced stock research and analysis. Our research team comprises of Financial Professionals). Analyst Update Guggenheim Securities has reiterated its 'Sell' rating on Tesla, Inc. and maintained a 12-month price target of $175.00 ahead of the company's upcoming earnings release. The bearish stance reflects concerns over margin pressure, demand uncertainty, and intensifying global EV competition, particularly from Chinese automakers. Guggenheim analysts have previously flagged issues related to Tesla's price cuts across key markets like the U.S., China, and Europe, which may weigh on profitability in the near term. Additionally, investors remains skeptical about Tesla's AI and Full Self-Driving (FSD) monetization timeline and sees limited upside in the core auto business without significant breakthroughs. Maintaining the 'Sell' rating before earnings also signals that Guggenheim anticipates underwhelming quarterly performance or cautious forward guidance from Tesla's management, especially in light of macroeconomic headwinds, slowing global EV sales, and the lack of major new vehicle launches in the current pipeline. Consensus Outlook Tesla currently holds a 'Hold' consensus rating from Wall Street analysts, reflecting a balanced but cautious sentiment. While some analysts remain bullish on Tesla's long-term technological and operational potential, others cite concerns around near-term valuation, profit margins, and competitive pressures. This mixed view is further evidenced by the average 12-month price target of approximately $300, which is below the current trading price—a signal that, in the eyes of analysts, Tesla may be overvalued at current levels.
CTV News
23 minutes ago
- CTV News
Keswick man wins $1 million jackpot, marking 3rd lottery win
Most people don't win much more than a free play with the lottery, but one Keswick man is celebrating his third big lottery win, marking his most significant yet. Neil Carter has been playing the lottery for four decades. Nine years ago he won $15,000 with an instant scratch ticket and last October, he took home $350,000 with a Lottario ticket. But now, the retired father of three upgraded to becoming an instant millionaire after winning $1 million with a ticket he purchased on a whim. "I went to the store for groceries, and while I was paying, I saw two Millionaire Multiplier tickets displayed on the counter,' he recalled. 'I decided to buy both of them.' Once home, Carter played his tickets, revealing his lucky streak was on a roll. 'I was shocked,' he said. 'I just couldn't believe it.' He called over his wife to double check on her phone using the OLG app. 'When she scanned it and saw that it was a big winner, she was in disbelief as well. We were both stunned and thrilled at the same time.' The new millionaire plans to buy and house and save for the future. 'Being a winner feels miraculous,' he shared. 'You never know if you'll be the one.' Carter purchased his winning ticket at Zehrs on Woodbine Avenue in Keswick. Millionaire Multiplier costs $100 per play and has a top prize of $1 million.
